Actively Recruiting
Individually Targeted Neuromodulation for Contamination-based OCD
Led by Mclean Hospital · Updated on 2024-03-15
50
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
M
Mclean Hospital
Lead Sponsor
M
Massachusetts General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with obsessive-compulsive disorder (OCD) experience a wide array of different types of obsessions and compulsions. However, current treatments for OCD employ a "one size fits all" approach and are used for all patients regardless of symptom type. In this project, the investigators propose to investigate whether a novel method of transcranial magnetic stimulation specifically reduces contamination/washing symptoms - one of the most common types of OCD.
CONDITIONS
Official Title
Individually Targeted Neuromodulation for Contamination-based OCD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 to 55 years
- Diagnosis of OCD as the primary disorder according to DSM-5
- Contamination/washing is the predominant symptom dimension on the Dimensional Yale-Brown Obsessive Compulsive Scale (D-YBOCS)
- Score of 8 or higher on the contamination dimension of the D-YBOCS
- Not taking psychiatric medications or on a stable dose of SSRI, clomipramine, SNRI, or second generation antipsychotic for at least 4 weeks before enrollment
- Use of PRN benzodiazepines allowed if dose and usage have been stable before enrollment
- No medication changes allowed during the study
- No new exposure and response prevention (ERP) therapy started within 4 weeks before enrollment
- Ongoing ERP therapy allowed if started more than 8 weeks before enrollment
You will not qualify if you...
- Positive urine drug screen except for prescribed benzodiazepines
- Use of psychiatric medications other than those permitted in the inclusion criteria
- Substance use disorder within the last 3 months, except nicotine
- History of schizophrenia, bipolar disorder, autism, or Tourette's syndrome
- Active suicidal thoughts in the week before screening
- History of traumatic brain injury, seizure disorder, neurodegenerative disease, or other organic brain disease
- Pregnancy or currently breastfeeding
- Contraindications for MRI scanning or transcranial magnetic stimulation (TMS)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
McLean Hospital
Belmont, Massachusetts, United States, 02478
Actively Recruiting
Research Team
R
Rosalind Sokoll
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here